CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies.
Identifieur interne : 000388 ( Main/Exploration ); précédent : 000387; suivant : 000389CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies.
Auteurs : E K Maina [Kenya] ; E Y Bonney [Ghana] ; E A Bukusi [Kenya] ; M. Sedegah [États-Unis] ; M. Lartey [Ghana] ; W K Ampofo [Ghana]Source :
- Immunology letters [ 1879-0542 ] ; 2015.
Descripteurs français
- KwdFr :
- Agents antiVIH (usage thérapeutique), Europe, Facteurs temps, Guides de bonnes pratiques cliniques comme sujet, Humains, Infections à VIH (immunologie), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Numération des lymphocytes CD4, Organisation mondiale de la santé, VIH (Virus de l'Immunodéficience Humaine) (), VIH (Virus de l'Immunodéficience Humaine) (immunologie), VIH (Virus de l'Immunodéficience Humaine) (physiologie), États-Unis d'Amérique.
- MESH :
- immunologie : Infections à VIH, VIH (Virus de l'Immunodéficience Humaine).
- physiologie : VIH (Virus de l'Immunodéficience Humaine).
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH.
- virologie : Infections à VIH.
- Europe, Facteurs temps, Guides de bonnes pratiques cliniques comme sujet, Humains, Numération des lymphocytes CD4, Organisation mondiale de la santé, VIH (Virus de l'Immunodéficience Humaine), États-Unis d'Amérique.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Anti-HIV Agents (therapeutic use), CD4 Lymphocyte Count, Europe, HIV (drug effects), HIV (immunology), HIV (physiology), HIV Infections (drug therapy), HIV Infections (immunology), HIV Infections (virology), Humans, Practice Guidelines as Topic, Time Factors, United States, World Health Organization.
- MESH :
- chemical , therapeutic use : Anti-HIV Agents.
- geographic : Europe, United States.
- drug effects : HIV.
- drug therapy : HIV Infections.
- immunology : HIV, HIV Infections.
- physiology : HIV.
- virology : HIV Infections.
- CD4 Lymphocyte Count, Humans, Practice Guidelines as Topic, Time Factors, World Health Organization.
Abstract
The primary goal when devising strategies to define the start of therapy in HIV infected individuals is to avoid HIV disease progression and toxicity from antiretroviral therapy (ART). Intermediate goals includes, avoiding resistance by suppressing HIV replication, reducing transmission, limiting spread and diversity of HIV within the body and protecting the immune system from harm. The question of how early or late to start ART and achieve both primary and intermediate goals has dominated HIV research. The distinction between early and late treatment of HIV infection is currently a matter of CD4+ T cells count, a marker of immune status, rather than on viral load, a marker of virus replication. Discussions about respective benefits of early or delayed therapy, as well as the best CD4+ T cell threshold during the course of HIV infection at which ART is initiated remains inconclusive. Guidelines issued by various agencies, provide different initiation recommendations. This can be confusing for clinicians and policy-makers when determining the best time to initiate therapy. Optimizing ART initiation strategies are clearly complex and must be balanced between individual and broader public health needs. This review assesses available data that contributes to the debate on optimal time to initiate therapy in HIV-infected asymptomatic individuals. We also review reports on CD4+ T cell threshold to guide initiation of ART and finally discuss arguments for and against early or late initiation of ART.
DOI: 10.1016/j.imlet.2015.10.005
PubMed: 26475399
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000367
- to stream PubMed, to step Curation: 000367
- to stream PubMed, to step Checkpoint: 000367
- to stream Ncbi, to step Merge: 000896
- to stream Ncbi, to step Curation: 000896
- to stream Ncbi, to step Checkpoint: 000896
- to stream Main, to step Merge: 000388
- to stream Main, to step Curation: 000388
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies.</title><author><name sortKey="Maina, E K" sort="Maina, E K" uniqKey="Maina E" first="E K" last="Maina">E K Maina</name><affiliation wicri:level="4"><nlm:affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana; Centre for Microbiology Research, Kenya Medical Research Institute, Kenya. Electronic address: emaina02@yahoo.com.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana; Centre for Microbiology Research, Kenya Medical Research Institute</wicri:regionArea><orgName type="university">Université du Ghana</orgName><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Bonney, E Y" sort="Bonney, E Y" uniqKey="Bonney E" first="E Y" last="Bonney">E Y Bonney</name><affiliation wicri:level="4"><nlm:affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana</wicri:regionArea><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university">Université du Ghana</orgName></affiliation></author><author><name sortKey="Bukusi, E A" sort="Bukusi, E A" uniqKey="Bukusi E" first="E A" last="Bukusi">E A Bukusi</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Microbiology Research, Kenya Medical Research Institute, Kenya.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>Centre for Microbiology Research, Kenya Medical Research Institute</wicri:regionArea><wicri:noRegion>Kenya Medical Research Institute</wicri:noRegion></affiliation></author><author><name sortKey="Sedegah, M" sort="Sedegah, M" uniqKey="Sedegah M" first="M" last="Sedegah">M. Sedegah</name><affiliation wicri:level="1"><nlm:affiliation>Malaria Program, Naval Medical Research Centre, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Malaria Program, Naval Medical Research Centre</wicri:regionArea><wicri:noRegion>Naval Medical Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Lartey, M" sort="Lartey, M" uniqKey="Lartey M" first="M" last="Lartey">M. Lartey</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, School of Medicine & Dentistry, CHS, University of Ghana, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, School of Medicine & Dentistry, CHS, University of Ghana</wicri:regionArea><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university">Université du Ghana</orgName></affiliation></author><author><name sortKey="Ampofo, W K" sort="Ampofo, W K" uniqKey="Ampofo W" first="W K" last="Ampofo">W K Ampofo</name><affiliation wicri:level="4"><nlm:affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana</wicri:regionArea><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university">Université du Ghana</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26475399</idno><idno type="pmid">26475399</idno><idno type="doi">10.1016/j.imlet.2015.10.005</idno><idno type="wicri:Area/PubMed/Corpus">000367</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000367</idno><idno type="wicri:Area/PubMed/Curation">000367</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000367</idno><idno type="wicri:Area/PubMed/Checkpoint">000367</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000367</idno><idno type="wicri:Area/Ncbi/Merge">000896</idno><idno type="wicri:Area/Ncbi/Curation">000896</idno><idno type="wicri:Area/Ncbi/Checkpoint">000896</idno><idno type="wicri:Area/Main/Merge">000388</idno><idno type="wicri:Area/Main/Curation">000388</idno><idno type="wicri:Area/Main/Exploration">000388</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies.</title><author><name sortKey="Maina, E K" sort="Maina, E K" uniqKey="Maina E" first="E K" last="Maina">E K Maina</name><affiliation wicri:level="4"><nlm:affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana; Centre for Microbiology Research, Kenya Medical Research Institute, Kenya. Electronic address: emaina02@yahoo.com.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana; Centre for Microbiology Research, Kenya Medical Research Institute</wicri:regionArea><orgName type="university">Université du Ghana</orgName><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName></affiliation></author><author><name sortKey="Bonney, E Y" sort="Bonney, E Y" uniqKey="Bonney E" first="E Y" last="Bonney">E Y Bonney</name><affiliation wicri:level="4"><nlm:affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana</wicri:regionArea><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university">Université du Ghana</orgName></affiliation></author><author><name sortKey="Bukusi, E A" sort="Bukusi, E A" uniqKey="Bukusi E" first="E A" last="Bukusi">E A Bukusi</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Microbiology Research, Kenya Medical Research Institute, Kenya.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>Centre for Microbiology Research, Kenya Medical Research Institute</wicri:regionArea><wicri:noRegion>Kenya Medical Research Institute</wicri:noRegion></affiliation></author><author><name sortKey="Sedegah, M" sort="Sedegah, M" uniqKey="Sedegah M" first="M" last="Sedegah">M. Sedegah</name><affiliation wicri:level="1"><nlm:affiliation>Malaria Program, Naval Medical Research Centre, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Malaria Program, Naval Medical Research Centre</wicri:regionArea><wicri:noRegion>Naval Medical Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Lartey, M" sort="Lartey, M" uniqKey="Lartey M" first="M" last="Lartey">M. Lartey</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, School of Medicine & Dentistry, CHS, University of Ghana, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Medicine, School of Medicine & Dentistry, CHS, University of Ghana</wicri:regionArea><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university">Université du Ghana</orgName></affiliation></author><author><name sortKey="Ampofo, W K" sort="Ampofo, W K" uniqKey="Ampofo W" first="W K" last="Ampofo">W K Ampofo</name><affiliation wicri:level="4"><nlm:affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana</wicri:regionArea><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName><orgName type="university">Université du Ghana</orgName></affiliation></author></analytic><series><title level="j">Immunology letters</title><idno type="eISSN">1879-0542</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (therapeutic use)</term><term>CD4 Lymphocyte Count</term><term>Europe</term><term>HIV (drug effects)</term><term>HIV (immunology)</term><term>HIV (physiology)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>HIV Infections (virology)</term><term>Humans</term><term>Practice Guidelines as Topic</term><term>Time Factors</term><term>United States</term><term>World Health Organization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (usage thérapeutique)</term><term>Europe</term><term>Facteurs temps</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Numération des lymphocytes CD4</term><term>Organisation mondiale de la santé</term><term>VIH (Virus de l'Immunodéficience Humaine) ()</term><term>VIH (Virus de l'Immunodéficience Humaine) (immunologie)</term><term>VIH (Virus de l'Immunodéficience Humaine) (physiologie)</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à VIH</term><term>VIH (Virus de l'Immunodéficience Humaine)</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>VIH (Virus de l'Immunodéficience Humaine)</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>HIV</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>CD4 Lymphocyte Count</term><term>Humans</term><term>Practice Guidelines as Topic</term><term>Time Factors</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Europe</term><term>Facteurs temps</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Numération des lymphocytes CD4</term><term>Organisation mondiale de la santé</term><term>VIH (Virus de l'Immunodéficience Humaine)</term><term>États-Unis d'Amérique</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The primary goal when devising strategies to define the start of therapy in HIV infected individuals is to avoid HIV disease progression and toxicity from antiretroviral therapy (ART). Intermediate goals includes, avoiding resistance by suppressing HIV replication, reducing transmission, limiting spread and diversity of HIV within the body and protecting the immune system from harm. The question of how early or late to start ART and achieve both primary and intermediate goals has dominated HIV research. The distinction between early and late treatment of HIV infection is currently a matter of CD4+ T cells count, a marker of immune status, rather than on viral load, a marker of virus replication. Discussions about respective benefits of early or delayed therapy, as well as the best CD4+ T cell threshold during the course of HIV infection at which ART is initiated remains inconclusive. Guidelines issued by various agencies, provide different initiation recommendations. This can be confusing for clinicians and policy-makers when determining the best time to initiate therapy. Optimizing ART initiation strategies are clearly complex and must be balanced between individual and broader public health needs. This review assesses available data that contributes to the debate on optimal time to initiate therapy in HIV-infected asymptomatic individuals. We also review reports on CD4+ T cell threshold to guide initiation of ART and finally discuss arguments for and against early or late initiation of ART.</div></front></TEI><affiliations><list><country><li>Ghana</li><li>Kenya</li><li>États-Unis</li></country><region><li>Région du Grand Accra</li></region><settlement><li>Accra</li><li>Legon (Ghana)</li></settlement><orgName><li>Université du Ghana</li></orgName></list><tree><country name="Kenya"><region name="Région du Grand Accra"><name sortKey="Maina, E K" sort="Maina, E K" uniqKey="Maina E" first="E K" last="Maina">E K Maina</name></region><name sortKey="Bukusi, E A" sort="Bukusi, E A" uniqKey="Bukusi E" first="E A" last="Bukusi">E A Bukusi</name></country><country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Bonney, E Y" sort="Bonney, E Y" uniqKey="Bonney E" first="E Y" last="Bonney">E Y Bonney</name></region><name sortKey="Ampofo, W K" sort="Ampofo, W K" uniqKey="Ampofo W" first="W K" last="Ampofo">W K Ampofo</name><name sortKey="Lartey, M" sort="Lartey, M" uniqKey="Lartey M" first="M" last="Lartey">M. Lartey</name></country><country name="États-Unis"><noRegion><name sortKey="Sedegah, M" sort="Sedegah, M" uniqKey="Sedegah M" first="M" last="Sedegah">M. Sedegah</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000388 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000388 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26475399
|texte= CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26475399" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |